Consequences of canceling elective invasive cardiac procedures during Covid‐19 outbreak

Abstract

Background During COVID‐19 pandemic in Spain, elective procedures were canceled or postponed, mainly due to health care systems overwhelming. Objective The objective of this study was to evaluate the consequences of interrupting invasive procedures in patients with chronic cardiac diseases due to the COVID‐19 outbreak in Spain. Methods The study population is comprised of 2,158 patients that were pending on elective cardiac invasive procedures in 37 hospitals in Spain on the 14th of March 2020, when a state of alarm and subsequent lockdown was declared in Spain due to the COVID‐19 pandemic. These patients were followed‐up until April 31th. Results Out of the 2,158 patients, 36 (1.7%) died. Mortality was significantly higher in patients pending on structural procedures (4.5% vs. 0.8%, respectively; p < .001), in those >80 year‐old (5.1% vs. 0.7%, p < .001), and in presence of diabetes (2.7% vs. 0.9%, p = .001), hypertension (2.0% vs. 0.6%, p = .014), hypercholesterolemia (2.0% vs. 0.9%, p = .026) [Correction added on December 23, 2020, after first online publication: as per Dr. Moreno's request changes in p‐values were made after original publication in Abstract.], chronic renal failure (6.0% vs. 1.2%, p < .001), NYHA > II (3.8% vs. 1.2%, p = .001), and CCS > II (4.2% vs. 1.4%, p = .013), whereas was it was significantly lower in smokers (0.5% vs. 1.9%, p = .013). Multivariable analysis identified age > 80, diabetes, renal failure and CCS > II as independent predictors for mortality. Conclusion Mortality at 45 days during COVID‐19 outbreak in patients with chronic cardiovascular diseases included in a waiting list due to cancellation of invasive elective procedures was 1.7%. Some clinical characteristics may be of help in patient selection for being promptly treated when similar situations happen in the future.

Transcatheter aortic valve implantation for degenerated aortic valves: Experience with a new supra‐annular device. The Spanish Allegra valve‐in‐valve (SAVIV) registry

“…During the study period, 29 patients with degenerated aortic valve bioprosthesis were treated with TAVI in Spain (Figure 1). Despite COVID‐19 pandemic, that tremendously impacted on the activity of the catheterization laboratories during 2020, 13,14 ≈50% of patients were included in this year.…”

Managing a Department of Obstetrics and Gynecology in Times of COVID-19 Outbreak: The Foch Hospital Experience

“…While controlling this communicable disease is of utmost importance, the long-term effect on individuals is significant. COVID 19 has negatively impacted patients with other diseases due to canceled care (14). That's why, we tried as soon as possible to restore a normal activity following the first lockdown.…”

Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19

“…Should proactive pharmacogenomicsinformed medication management for COVID-19 patients successfully reduce LOS, even non-COVID patients could benefit by reducing the burden on overwhelmed healthcare systems that have delayed some patient care. 16,[33][34][35] In addition, pharmacogenomic intervention could reduce COVID-19 healthcare costs. Estimating the potential cost savings from a reduction in LOS is challenging; however, recent data show that the average Medicare payment per COVID-19 hospitalization is $23,587, 18 which is $8,688 higher than the average Medicare Advantage hospitalization ($14,900).…”